Intravenous Iron Replacement Therapy Improves Cardiovascular Outcomes in Hemodialysis Patients

MATTEO RIGHINI¹, VITTORIO DALMASTRI², IRENE CAPELLI¹, CLAUDIO ORSI², GABRIELE DONATI¹, MARIA GIOVANNA PALLOTTI³, CHIARA PEDONE³, GIANNI CASELLA³, PASQUALE CHIECO⁴ and GAETANO LA MANNA¹

¹Department of Nephrology, Dialysis and Transplantation, Policlinico Sant’Orsola Malpighi, Bologna, Italy;
²Department of Nephrology and Dialysis, Maggiore Hospital, Bologna, Italy;
³Department of Cardiology, Maggiore Hospital, Bologna, Italy;
⁴Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy

Abstract. Background/Aim: More than half of deaths among hemodialysis patients are due to cardiovascular disease. This study examined whether intravenous administration of ferric carboxymaltose (FCM) has an impact on cardiovascular events in iron-deficient hemodialysis patients. Patients and Methods: We performed a retrospective study concerning patients undergoing hemodialysis in our center from September 2016 to December 2019. We identified those who began FCM therapy (FCM group) during this period and those who did not (control group). We analyzed clinical, echocardiographic and laboratory parameters at the beginning (t0) and after one year (t1), to detect differences between the two groups. Results: We identified 53 patients for the FCM group and 19 for the control group. Median follow-up was 1 year±3 months for both groups. In the FCM group, we observed a reduction in the doses of erythropoiesis-stimulating agents (ESA) (p<0.001) and a significant difference in cardiovascular events (p<0.01), but no differences in echocardiographic parameters. Conclusion: Patients who received FCM reached satisfactory values of transferrin saturation and ferritin, presented fewer coronary artery events and cardiovascular events, and could reduce doses of ESA.

Patients with end stage renal disease (ESRD) are among the highest risk populations for cardiovascular disease (CVD). As depicted by the 2018 United States Renal Data System (USRDS) register (1), the prevalence of CVD in patients who received hemodialysis (HD) is 70.6%. There are many changes secondary to renal dysfunction that lead to cardiac dysfunction, including fluid overload, uremic cardiomyopathy, secondary hyperparathyroidism, altered lipid metabolism, accumulation of gut microbiota-derived toxins, anemia, iron deficiency (ID) and HD (2-4). In anemic patients with chronic kidney disease (CKD), iron replacement is an established part of disease management, resulting in increased hemoglobin levels, decreased concomitant therapy with erythropoiesis-stimulating agents (ESA), and stabilized renal function (5-7). The importance of ID in cardiac heart failure (CHF) has only recently drawn clinical attention, however, several studies have shown that it could be present independently of anemia, predicts poor outcome, reduced exercise capacity and impaired quality of life (8-12). Iron plays a central role in the uptake, transport, storage and metabolism of oxygen, and it is involved in erythropoiesis and cellular immune response. According to a few studies, ID directly affects human cardiomyocyte function, impairing mitochondrial respiration, and reducing contractility and relaxation; restoration of intracellular iron levels can reverse these effects (13, 14). In addition, several studies have demonstrated that CKD patients who underwent ferric carboxymaltose (FCM) treatment had fewer hospitalizations for any cardiovascular cause and experienced cardiac disorders less frequently (7). Moreover, a PIVOTAL study showed that high dose FCM was associated with a lower risk of death or major adverse CVE (15).

We analyzed the effects of intravenous FCM on the anemia profile and whether it had an impact on the reduction of CVE in our HD population, on reducing ESA.

This article is freely accessible online.

Correspondence to: Gaetano La Manna, Nephrology, Dialysis and Renal Transplant Unit, S. Orsola Hospital Bologna, Via Massarenti 9, 40100 Bologna, Italy. Tel: +39 0512143255, Fax: +39 051340871, e-mail: gaetano.lamanna@unibo.it

Key Words: Anaemia, cardiovascular disease, echocardiography, haemodialysis, iron.
dose or on determining some cardiac modifications in a period of one year.

Patients and Methods

We performed a case-control retrospective study concerning patients undergoing hemodialysis in Policlinico Sant’Orsola and Maggiore Hospital in Bologna from September 2016 and December 2019. During our observation period, we collected demographics parameters (sex and age), clinical parameters (diabetes, hypertension, comorbidities), dialytic parameters (age of dialysis, frequency, vascular access), doses of ESA and doses of FCM.

We included all patients older than 18 years old, who performed hemodialysis for at least one year. We excluded all patients who previously received kidney transplantation, who in the previous 3 months received intravenous iron therapy and who in the last year presented an episode of coronary artery event, cerebrovascular event (stroke or TIA), de novo or relapsing CHF, or a symptomatic episode of atrial fibrillation. We did not exclude patients who presented allergies to different formulations of intravenous iron or polyclerigic patients. The research was conducted ethically in accordance to the World Medical Association Declaration of Helsinki. Subjects provided written informed consent and the Local Ethical Committee approved the study.

Analysis was performed at the beginning of FCM therapy (t0) and one year later (t1), and included:

- laboratory values: Hemoglobin, mean corpuscular volume (MCV), serum iron, transferrin, ferritin, saturation of transferrin (sTF), C reactive protein (CRP), acid uric, total cholesterol, LDL, HDL, triglycerides;
- echocardiographic parameters: ejection fraction (EF), telediastolic left atrial volume, telediastolic interventricular septum, telesystolic interventricular septum, telediastolic left ventricular volume, E wave, A wave, and E/A. Echocardiographs were performed by several cardiologists of the Cardiology Unit of Maggiore Hospital and of Policlinico Sant’Orsola.

Our population was divided into two groups, one that received FCM (study group) and one that did not (control group). FCM is a new intravenous iron preparation (molecular weight 150,000 Daltons) that comprises an iron carbohydrate complex that allows iron to be slowly released, avoiding toxicity and oxidative stress. Two ml (100 mg) of undiluted FCM was administered during the last 15-20 min of hemodialysis treatment directly in the venous circuit (16).

At one year, the role of demographic, laboratory, echocardiographic and dialytic parameters was investigated. We also analyzed the incidence of CVE expressed as a coronary artery event, cerebrovascular event (stroke or TIA), de novo or relapse of CHF, symptomatic episode of atrial fibrillation as well as the reduction of ESA.

Data were obtained from the digital medical records and a database was created specifically for the study. The study was approved by the Local Ethics Committee (n°148/2019).

Statistical analysis. Quantitative data are presented as mean±standard deviation or as median and interquartile range (IQR) when appropriate, while qualitative data were expressed as an absolute or relative (percent) frequency. Correlations were assessed using Pearson’s or Spearman’s method for normally or non-normally distributed data, respectively. The quantitative parameter distributions were analyzed by Skewness and Kustosis normality test. The chi-square test (Fisher’s exact test for small numbers) was used to compare the categorical variables. Student’s t-test and Kruskal-Wallis were used to compare quantitative parameters with a symmetric or asymmetric distribution, respectively. A p-value <0.05 was considered statistically significant. The statistical analysis was performed using STATA (Statistical software, Version 13-StataCorp LP, College Station, TX, USA).

Results

Following evaluation, we selected 72 patients undergoing hemodialysis. We split our population into two groups: the study group (53 patients) that received FCM (median dose 656.6 mg/month) and the control group (19 patients) that did not receive iron replacement therapy for clinical reasons. The study group (FCM group) included 33 men (62.3%), and the control group (CG) 14 (73.7%). The median age was 64.82±15.29 years old and the most representative age was in the range of 61 to 80 years old. We considered the presence of diabetes (23 patients, 31.9%) and hypertension (51 patients, 70.8%). Regarding dialysis frequency, 61 patients (84.7%) underwent dialysis three times per week, 9 (12.5%) underwent dialysis twice per week and only 2 (2.8%) patients belonging to the FCM group performed 4 dialysis per week. In our population, the mean years of dialysis were 6.15±4.51 years. Regarding vascular access, our population included 39 patients (54.2%) with proximal arterio-venous fistula (pAVF), 24 (33.3%) with distal arterio-venous fistula (dAVF) and 9 (12.5%) with central venous catheter (CVC). These results and subgroup differences are summarized in Table I.

As described above, for each patient, we evaluated laboratory results and echocardiograms performed at the beginning of FCM therapy (t0) and after 12±3 months (t1). We analyzed an analogue period for the group who did not receive iron therapy.

In our population, Hb values of 10.44±1.77 g/dl at t(0) and of 11.11±1.29 g/dl at t(1) were recorded. The group that received FCM showed an increase in Hb of 6.79% during the study period, while the control group showed a minor increase. MCV was also evaluated considering that our patients could have a mixed anemia (normocytic and microcytic). MCV was found to be 92.8±9.7 fL at t(0) and 97±8.8 fL at t(1). This increasing trend occurred in both subgroups without a significative difference. CRP was also evaluated as an inflammation marker because it could influence our results; nevertheless, mean CRP values were 0.45±0.35 mg/dl at t(0) and 0.42±0.38 mg/dl at t(1) without difference between groups.

Then, we evaluated the iron balance expressed as serum iron, ferritin, transferrin, and sTF. The results are presented in Table II. In our population, serum iron was 50.3±22.3 μg/dl at t(0) and 55.6±25.6 μg/dl at t(1). This increase was prominent in the FCM group. Furthermore, ferritin was
sufficient in both groups; in the whole population, mean ferritin was 302.5±389.9 ng/ml at t(0) and 466.7±422.6 ng/ml at t(1), showing an increase of 54.28% in the FCM group and a reduction of 8.23% in the CG. The different trend between the two groups was relevant ($p < 0.001$). As for ferritin, even sTF presented an analogous trend, increasing from 18.1±10.3% at t(0) to 24.2±12.9% at t(1). In the FCM group, as expected, we noticed a higher increase (33.96% vs.15.3%) with a significant difference between the two groups ($p < 0.001$) (Figure 1).

To treat anemia in CKD patients ESA are prescribed. In our population, the mean dose of ESA at t(0) was 19,055.6±8,226.4 U/week whereas at t(1) it was 17,111.1±9,099.6 U/week. The variation in the dose of ESA was consistent between the two groups (-16.8% vs. +3.6%, $p<0.001$).

We also analyzed the relationship between iron balance and echocardiographic aspects in HD patients including the Ejection Fraction (EF, 72 patients), left atrial volume (LAV, 52 patients), left ventricular telediastolic volume (LVDV, 40 patients), and telediastolic interventricular septum diameter (SIV td, 51 patients). Then, we recorded E/A variations to investigate diastolic function. E wave corresponds to the rapid ventricular replacement, when after the isovolumetric release, atrial pressure exceeds the ventricular one. A wave expresses the second peak in the transmitralic pattern and corresponds to atrial systole. The E/A ratio could distinguish 4 diastolic patterns of trans-mitralic flux: normal, altered diastolic release, pseudonormal pattern and restrictive pattern. In our population, E/A was available for 28 patients.

### Table I. Population and subgroup characteristics.

| Table I. Population and subgroup characteristics. | Population | FCM group | Control group |
|--------------------------------------------------|------------|-----------|---------------|
| No. patients                                      | 72         | 53        | 19            |
| Gender                                           |            |           |               |
| M                                                | 47 (65.3%) | 33 (62.3%)| 14 (73.7%)    |
| F                                                | 25 (34.7%) | 20 (37.7%)| 5 (26.3%)     |
| Age (med±SD)                                     | 64.8±15.3  | 65±15.3   | 64.4±15.6     |
| <40 y                                            | 5 (6.9%)   | 3 (5.7%)  | 2 (10.5%)     |
| 41-60                                            | 18 (25%)   | 15 (28.3%)| 3 (15.8%)     |
| 61-80                                            | 38 (52.8%) | 26 (49.1%)| 12 (63.2%)    |
| >80                                              | 11 (15.3%) | 9 (17%)   | 2 (10.5%)     |
| Diabetes                                         | 23 (31.9%) | 19 (35.8%)| 4 (21%)       |
| Hypertension                                     | 51 (70.8%) | 41 (77.4%)| 10 (52.6%)    |

### Table II. Blood analysis at t(0) and t(1) expressed as percentage variations in one year. Significant results were observed for sTF, ferritin and ESA weekly dose.

| Table II. Blood analysis at t(0) and t(1) expressed as percentage variations in one year. Significant results were observed for sTF, ferritin and ESA weekly dose. | FCM group | Control group | p-Value |
|--------------------------------------------------------------------------------------------------------------------------------|-----------|---------------|---------|
| Hb g/dl                                                                                                                          |            |               | 0.09    |
| t(0)                                                                                                                            | 10.6±1.4  | 10.5±1.6      |
| t(1)                                                                                                                            | 11.1±1.3  | 11.1±1.3      |
| Δ                                                                | +6.5%      | +6.8%         |         |
| MCV fl                                                                                                                          |            |               | 0.05    |
| t(0)                                                                                                                            | 92.8±10.9 | 93±4.8        |
| t(1)                                                                                                                            | 97.2±8.7  | 96.3±9.2      |
| Δ                                                                | +5.9%      | +3.7%         |         |
| Total Cholesterol mg/dl                                                                                                           |            |               | 0.3     |
| t(0)                                                                                                                            | 157±66.7  | 164.7±49      |
| t(1)                                                                                                                            | 169.4±44.8| 152.7±55.5    |
| Δ                                                                | +7.67%     | -7.3%         |         |
| LDL mg/dl                                                                                                                        |            |               | 0.44    |
| t(0)                                                                                                                            | 94.5±45.6 | 102.2±45.2    |
| t(1)                                                                                                                            | 90±43.3   | 88.2±39.7     |
| Δ                                                                | -4.09%     | -13.7%        |         |
| HDL mg/dl                                                                                                                        |            |               | 0.19    |
| t(0)                                                                                                                            | 49±18.1   | 41.4±14       |
| t(1)                                                                                                                            | 52±34.8   | 51±21.7       |
| Δ                                                                | +4.6%      | +26.4%        |         |
| Triglycerids mg/dl                                                                                                                |            |               | 0.55    |
| t(0)                                                                                                                            | 152.4±74  | 158.4±57.9    |
| t(1)                                                                                                                            | 151.4±44.1| 134.5±61.8    |
| Δ                                                                | -0.7%      | -15.1%        |         |
| Uric Acid mg/dl                                                                                                                  |            |               | 0.06    |
| t(0)                                                                                                                            | 6±0.9     | 6.8±1.4       |
| t(1)                                                                                                                            | 6.5±0.9   | 6.8±1.4       |
| Δ                                                                | +6%        | +3.5%         |         |
| C reactive Protein mg/dl                                                                                                          |            |               | 0.44    |
| t(0)                                                                                                                            | 0.48±0.46 | 0.39±0.27     |
| t(1)                                                                                                                            | 0.45±0.38 | 0.41±0.39     |
| Δ                                                                | -6%        | +5%           |         |
| Serum iron mcg/dl                                                                                                                |            |               | 0.34    |
| t(0)                                                                                                                            | 48.5±20   | 55.8±27.8     |
| t(1)                                                                                                                            | 55.3±25.3 | 56.7±27.2     |
| Δ                                                                | +14.1%     | +1.6%         |         |
| sTF (%)                                                                                                                          |            |               | 0.34    |
| t(0)                                                                                                                            | 18±10.3   | 19±10.5       |
| t(1)                                                                                                                            | 24±12.9   | 22±12.9       |
| Δ                                                                | 34%        | 15.3%         |         |
| Ferritin mg/ml                                                                                                                   |            |               | <0.001  |
| t(0)                                                                                                                            | 302.5±382.9| 532.8±1,220  |
| t(1)                                                                                                                            | 466.7±422.6| 489±1,341.3  |
| Δ                                                                | 54%        | -8%           |         |

FCM: Ferric carboxymaltose; M: male; F: female; SD: standard deviation; y: years; pAVF: proximal arterovenous fistula; dAVF: distal arterovenous fistula; CVC: central venous catheter.
Although we observed several differences between the two groups, no significant variations were recorded in our echocardiographic values (Table III).

Similarly to recent studies, we examined whether FCM therapy in our population could reduce the incidence of cardiovascular events (CVE); therefore, we evaluated coronary artery event (CA), cerebrovascular event (stroke or TIA), de novo or relapse of CHF, symptomatic episode of atrial fibrillation (AF). In the whole population, we observed 18 CVE in 15 patients (20.83%), 10 CA, 2 AF, 5 CHF, and 1 stroke. Analyzing the FCM group, we witnessed 9 CVE (16.98%) in 7 patients, 5 CA (9.43%) in 5 patients, 2 AF (3.77%) in 2 patients, 1 CHF (1.89%) and 1 stroke (1.89%). In this population, 2 patients (3.77%) presented multiple CVE in the considered period. Considering the CG, we also witnessed 9 CVE (47.37%) in 8 patients, 5 CA (26.32%) in 5 patients, no AF, 4 CHF (21.05%) in 4 patients and no strokes. The difference in the incidence of CVE and CA was statistically significantly different between the two groups (p<0.02, p<0.02). The distribution of CVE is shown in Figure 2. Then, we examined whether some conditions could influence our results but no statistical significance was reached among the different subgroups (Table IV).

Discussion

Anemia in HD patients has complex and multiple etiologies and significantly impairs quality of life. Several previous studies have shown that anemia is associated with higher risk of left ventricular hypertrophy, CVE, hospitalization and death (17-19). It is currently known that a lot of HD patients present iron deficiency because of reduced dietary intake, reduced gut absorption and increased gastrointestinal iron losses (20, 21). Intravenous iron replacement is often required for these patients in order to reduce ESA doses and to reach adequate Hb values; nevertheless, concerns have been raised regarding the safety of iron compounds due to the possibility of iron overload, oxidative stress, cardiovascular disease and hypersensitivity reactions (22, 23). On the other hand, even ESA therapy could result in many adverse clinical consequences such as stroke and venous thromboembolic disease, and some patients do not respond adequately to ESA (24-26).

In line with the NICE guidelines (27) and KDIGO recommendations on anemia management, our population received FCM therapy and showed no side effects or hypersensitivity reactions. None of our patients dismissed the therapy due to iron overload and we did not purposely exclude from our analysis patients who presented anamnestic iron reactions.

A significant difference in terms of CVE was observed between the group treated with FCM vs. the CG. Our results are in line with the study of Garcia et al. (28), who showed that high ESA dose is an independent predictor for all-cause, CVE and infectious hospitalization. The study focused on the

Figure 1. Changes in Hb, sTF and ferritin after one-year observation between the two groups. sTF and ferritin showed a significant increase in the group receiving FCM vs. the control group. Hb: Hemoglobin; sTF: transferrin saturation; FCM: ferric carboxymaltose.
As the authors suggested, we hypothesized that the dose sparing effect of intravenous iron therapy on ESA might contribute to the cardiovascular profile; our population received a higher mean dose of ESA than the one in that study, and the FCM group showed a decrease in the number of CVE compared to the CG, supporting the reduction in the dose of ESA.

Apart from its role in maintaining the oxygen-carrying capacity of the blood in erythropoiesis, iron is independently crucial for oxygen transport, delivery and utilization. Metabolically active cells (as myocytes) depend on iron for their function and structural integrity (29-31). Iron deficiency is prevalent in CHF and may be present independently of anemia; it predicts poor outcomes, reduces exercise capacity, and impairs quality of life (32, 33), however, though those studies were performed in patients who were not on HD. A study that set a milestone in the scientific community, was performed by Mcdougall et al. (15). In a population of over 2,000 patients undergoing HD, they showed that those who received a proactive dose (high dose, 200-400 mg/month) rather than a reactive dose (low dose, <200 mg/month) of FCM presented a significative reduction in the composite end-point (nonfatal myocardial infarction, nonfatal stroke, hospitalization for heart failure or death, assessed in a time to first event analysis). Our population received a higher dose of FCM (656.6 mg/month), without any adverse event. Supported by the data of the PIVOTAL study, we found that patients who received FCM had a reduced number of CVE compared to those who did not. Moreover, CVE among patients who received 800 mg/month were slightly inferior compared to those who received less than 400 mg/month. Our cohort reached high levels of ferritin and sTF, showing no increase of CVE during the year; however, one year of observation is a short period of time which does not allow us to reach definite conclusions, and does not take into account the accumulation of iron in tissues. Despite not reaching statistical significance, the highest number of CVE in our cohort was observed in the CG, with levels of ferritin <200 ng/ml.

Regarding sTF, without reaching statistical significance, we evidenced most CVE in those who presented low levels in both groups compared to those who reached satisfactory values. Our results are in line with a study by Fukuma et al. where values of ferritin <200 ng/ml and sTF<20% were associated with increased cardiovascular mortality (34).

We analyzed the correlation between vascular access and the incidence of CVE. The arteriovenous fistula (AVF) undoubtedly contributes to inflammation status, excess CV mortality in HD patients and a short life span (35-37). As described by Basile et al. (38), significant hemodynamic modifications of the cardiovascular system are associated with AVF. To our knowledge, there are no studies that correlate an improved iron balance, to specific hemodynamic modifications in HD patients; with this in mind, we analyzed the echocardiograms of our population. We noticed multiple changes in echocardiographic parameters in the FCM group compared to the CG. The most improved parameter was ejection fraction (EF) that showed an improvement in the...
Another improved parameter was SIVtd where a greater erythropoiesis stimulating agents; Hb: Haemoglobin; sTF: transferrin.

FCM: Ferric carboxymaltose; pAVF: proximal arteriovenous fistula; dAVF: distal arteriovenous fistula; CVC: central venous catheter; ESA: erythropoiesis stimulating agents; Hb: Haemoglobin; sTF: transferrin saturation.

Another improved parameter was SIVtd where a greater improvement was observed in the FCM group (4.52% vs. 1.76%). In the FCM group, most of CVE and CA occurred in those who received the FCM therapy. Echocardiography could be a useful tool for identifying progressive CVD in HD patients.

In conclusion, we demonstrated that FCM therapy had a beneficial impact on CVE in a HD population and helped reach satisfactory levels of Hb, ferritin, and sTF. Importantly it helped reduce the dose of ESA compared to those who did not receive the FCM therapy. Echocardiography could be a useful tool for identifying progressive CVD in HD patients.

### Conflicts of Interest

The Authors declare no conflicts of interest in relation to this study.

### Authors’ Contributions

Matteo Righini: contributed to study design, data collection, data analysis and article writing. Vittorio Dalmastri: contributed to study design and data collection. Irene Capelli: contributed to data analysis and paper writing. Claudio Orsi: contributed to data collection and reference collection. Gabriele Donati: contributed to article writing and final revision. Maria Giovanna Pallotti: contributed to echocardiography description and article writing. Chiara Pedone: contributed to study design, manuscript revision and data interpretation. Each Author contributed important intellectual content during manuscript drafting or revision, accepts personal accountability for the author’s own contributions, and agrees to ensure that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved.
References

1. 2018 USRDS Annual data report. Volume 2: ESRD in the United States, Chapter 8: Cardiovascular disease in patients with ESRD, pp. 501-518, 2018.

2. Ahmadmehrabi S and Tang WHW: Hemodialysis-induced cardiovascular disease. Semin Dial 33(3): 258-267, 2018. PMID: 29624739. DOI: 10.1111/sd.12694

3. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC and Barre PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28(1): 53-61, 1996. PMID: 8712222. DOI: 10.1016/s0272-6386(96)90130-4

4. Wish JB, Aroffon GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, Macdougall IC, Núñez J, Perahia AJ and Wood JC: Positive iron balance in chronic kidney disease: How much is too much and how to tell? Am J Nephrol 47(2): 72-83, 2018. PMID: 29439253. DOI: 10.1159/000486968

5. KDOQ and National Kidney Foundation: II. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis 47(5 Suppl 3): S16-S85, 2006. PMID: 16678661. DOI: 10.1053/j.ajkd.2006.03.011

6. Mircescu G, Gârneata L, Capusa C and Ursea N: Intravenous iron supplementation for the treatment of anemia in pre-dialyzed chronic renal failure patients. Nephrol Dial Transplant 21(1): 120-124, 2006. PMID: 16144853. DOI: 10.1093/ndt/gfi087

7. Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T, Gaudeusis G, von Eisenhart Rothe B, Mori C, Greenlaw N, Ford I, Macdougall I, Anker SD and FAIR-HF Trial Investigators: The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. Eur J Heart Fail 15(3): 329-339, 2013. PMID: 25863972. DOI: 10.1002/ejhf.229

8. Comín-Colet J, Enjuanes C, González G, Torrens A, Cladellas M, Meroño O, Ribas N, Ruiz S, Gómez M, Verdú JM and Bruguerà J: Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status. Eur J Heart Fail 15(10): 1164-1172, 2013. PMID: 23703106. DOI: 10.1002/ejhf.1089

9. Enjuanes C, Klip IT, Bruguerà J, Cladellas M, Ponikowski P, Banasiak W, van Veldhuisen DJ, van der Meer P, Jankowska EA and Comín-Colet J: Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study. Int J Cardiol 174(2): 268-275, 2014. PMID: 24768464. DOI: 10.1016/j.ijcard.2014.03.169

10. Jankowska EA, Rozentryt P, Witkowski A, Nowak J, Hartmann O, Ponikowski P, Borodulin-Nadzieja L, von Haehling S, Doehner W, Banasiak W, Polonski L, Filippatos G, Anker SD and Ponikowski P: Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail 17(11): 899-906, 2011. PMID: 22041326. DOI: 10.1016/j.cardfail.2011.08.003

11. Okonko DO, Mandal AK, Missouris CG and Poole-Wilson PA: Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival. J Am Coll Cardiol 58(12): 1241-1251, 2011. PMID: 21903058. DOI: 10.1016/j.jacc.2011.04.003

12. van Veldhuisen DJ, Anker SD, Ponikowski P and Macdougall IC: Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 8(9): 485-493, 2011. PMID: 21629210. DOI: 10.1038/nrcardio.2011.77

13. Dziewala M, Josiak K, Kasztura M, Kobak K, von Haeling S, Banasiak W, Anker SD, Ponikowski P and Jankowska E: Iron deficiency as energetic insult to skeletal muscle in chronic diseases. J Cachexia Sarcopenia Muscle 9(5): 802-815, 2018. PMID: 30178922. DOI: 10.1002/jcsm.12314

14. Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, Rodenburg RJ, van Veldhuisen DJ, de Boer RA and van der Meer P: Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur J Heart Fail 20(5): 910-919, 2018. PMID: 29484788. DOI: 10.1002/ejhf.1154

15. Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winears CG, Ford I and PIVOTAL Investigators and Committees: Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 380(5): 447-458, 2019. PMID: 30365356. DOI: 10.1056/NEJMoai1810742

16. Geisser P: The pharmacology and safety profile of ferrocene carbonate (Ferinject): structure/reactivity relationships of iron preparations. J Nephrol Hypert 23(1): 11-16, 2009.

17. Volkova N and Arab L: Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 47(1): 24-36, 2006. PMID: 16377382. DOI: 10.1053/ajkd.2005.09.007

18. Rocdzie L, Weigert A, Silva F, Frazão J, Alsuwaied A, Krishnan M, Kleophas W, Brzosko S, Johansson FK and Jacobson SH: Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis. BMC Nephrol 20(1): 5, 2019. PMID: 30616548. DOI: 10.1186/s12882-018-1196-7

19. Nangaku M and Eckardt KU: Pathogenesis of renal anemia. Semin Nephrol 26(4): 261-268, 2006. PMID: 16949463. DOI: 10.1016/j.sne nephrol.2006.06.001

20. Flint S, Taylor E, Beavis J, Becker GJ and Pedagogos E: Increased iron requirement in hemodialysis patients on antplatelet agents or warfarin. Nephron Clin Pract 113(1): c38-c45, 2009. PMID: 19590234. DOI: 10.1159/000228074

21. Rampton D, Folkersens J, Fishbain S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J and Weiss G: Hypersensitivity reactions to intravenous iron: Guidance for risk minimization and management. Haematologica 99(11): 1671-1676, 2014. PMID: 25420283. DOI: 10.3324/haematol.2014.111492

22. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C and Meyerstein DC: Anemia and iron deficiency as energetic insult to skeletal muscle in chronic diseases. J Cachexia Sarcopenia Muscle 9(5): 802-815, 2018. PMID: 30178922. DOI: 10.1002/jcsm.12314
Kidney Dis 53(5): 823-834, 2009. PMID: 19339087. DOI: 10.1053/j.kid.2008.12.040

Rosters J, Gassmann-Mayer C, Frei D and McClellan W: Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 22(3): 794-800, 2007. PMID: 17210593. DOI: 10.1093/ndt/gfl716

Ratcliffe LE, Thomas W, Glen J, Padhi S, Pordes BA, Wonderling D, Connell R, Stephens S, Mikhail AI, Fogarty DG, Cooper JK, Dring B, Devonald MA, Brown C and Thomas ME: Diagnosis and management of iron deficiency in CKD: A summary of the NICE guideline recommendations and their rationale. Am J Kidney Dis 67(4): 548-558, 2016. PMID: 26763385. DOI: 10.1093/ndt/gfx269

Anand IS and Gupta P: Anemia and iron deficiency in heart failure: Current concepts and emerging therapies. Circulation 138(1): 690-699, 2018. PMID: 29036505. DOI: 10.1093/circulation/aha.118.030099

Pérez-García R, Varas J, Cives A, Martín-Malo A, Aljama P, Ramos R, Pascual J, Stuard S, Canaud B, Merello JI and ORD group: Increased mortality in haemodialysis patients administered high doses of erythropoiesis-stimulating agents: A propensity score-matched analysis. Nephrol Dial Transplant 33(4): 4657-4668, 2015. PMID: 26797270. DOI: 10.1093/ndt/gfx840

Nakahoul F, Yigla M, Gilman R, Reinsier SA and Abassi Z: The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 20(8): 1686-1692, 2005. PMID: 15840664. DOI: 10.1093/ndt/gfh840

von Bibra H, Castro L, Autenrieth G, McLeod A and Gurland HJ: The effects of arteriovenous shunts on cardiac function in renal dialysis patients—an echocardiographic evaluation. Clin Nephrol 9(5): 295-302, 2017. PMID: 27647766. DOI: 10.1002/cnj.21102

Jankowska EA and Ponikowski P: Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin 6(3): 295-304, 2010. PMID: 20630404. DOI: 10.1016/j.hfc.2010.03.003

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegoswka J, Kirwan BA, Mori C, von Eisenhart Rothé B, Pocock SJ, Poole-Wilson PA, Ponikowski P and FAIR-HF Trial Investigators: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 361(25): 2436-2448, 2009. PMID: 19920854. DOI: 10.1056/NEJMoa0908355

Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev C, McDonagh T, Parkhomenko A, Tavazzi L, Levesque V, Mori C, Roubert B, Filippatos G, Ruschitzka F, Anker SD and CONFIRM-HF Investigators: Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 36(11): 657-668, 2015. PMID: 25176939. DOI: 10.1093/eurheartj/ehu385

Fukuma S, Yamaguchi T, Hashimoto S, Nakai S, Iseki K, Tsubakihara Y and Fukuhara S: Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: Results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 59(1): 108-116, 2012. PMID: 21890255. DOI: 10.1053/j.kid.2011.07.014

Coli L, Donati G, Cappuccilli ML, Cianciolo G, Comai G, Cuna V, Carretta E, La Manna G and Stefoni S: Role of the hemodialysis vascular access type in inflammation status and monocyte activation. Int J Artif Organs 34(6): 481-488, 2011. PMID: 21228578. DOI: 10.1159/000322695

Amerling R, Ronco C, Kuhlman M and Winchester JF: Arteriovenous fistula toxicity. Blood Purif 31(1-3): 113-120, 2011. PMID: 21228578. DOI: 10.1159/000322695

Basile C, Vernaglione L, Casucci F, Libutti P, Lisi P, Rossi L, Vigo V and Lomonte C: The impact of haemodialysis arteriovenous fistula on haemodynamic parameters of the cardiovascular system. Clin Kidney J 9(5): 729-734, 2016. PMID: 27679720. DOI: 10.1093/ckj/sfw063

Nakhoul F, Yigla M, Gilman R, Reinsier SA and Abassi Z: The pathogenesis of pulmonary hypertension in haemodialysis patients via arterio-venous access. Nephrol Dial Transplant 20(8): 1686-1692, 2005. PMID: 15840664. DOI: 10.1093/ndt/gfh840

von Bibra H, Castro L, Autenrieth G, McLeod A and Gurland HJ: The effects of arteriovenous shunts on cardiac function in renal dialysis patients—an echocardiographic evaluation. Clin Nephrol 9(5): 205-209, 1978. PMID: 657597.

Di Tullio MR, Qian M, Thompson JLP, Labovitz AJ, Mann DL, Saccu RL, Pullicino PM, Freudenger RS, Teerlink JR, Graham S, Lip GYH, Levin B, Mohr JP, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Homma S and WARCEF Investigators: Left atrial volume and cardiovascular outcomes in systolic heart failure: Effect of antithrombotic treatment. ESC Heart Fail 5(5): 800-808, 2018. PMID: 30015405. DOI: 10.1002/ehf2.12331

Garcia MJ, Ares MA, Asher C, Rodriguez L, Vandervoort P and Thomas JD: An index of early left ventricular filling that combined with pulsed Doppler peak E velocity may estimate capillary wedge pressure. J Am Coll Cardiol 29(2): 448-454, 1997. PMID: 9015003. DOI: 10.1016/s0735-1097(96)00496-2

Received February 27, 2021
Revised March 12, 2021
Accepted March 23, 2021

in vivo 35: 1617-1624 (2021)